Literature DB >> 31809024

Programmable Assembly of Adeno-Associated Virus-Antibody Composites for Receptor-Mediated Gene Delivery.

Alina C Zdechlik, Yungui He, Eric J Aird, Wendy R Gordon, Daniel Schmidt.   

Abstract

Adeno-associated virus (AAV) has emerged as a viral gene delivery vector that is safe in humans, able to infect both dividing and arrested cells and drive long-term expression (>6 months). Unfortunately, the naturally evolved properties of many AAV serotypes-including low cell type specificity and largely overlapping tropism-are mismatched to applications that require cell type-specific infection, such as neural circuit mapping or precision gene therapy. A variety of approaches to redirect AAV tropism exist, but there is still the need for a universal solution for directing AAV tropism toward user-defined cellular receptors that does not require extensive case-by-case optimization and works with readily available components. Here, we report AAV engineering approaches that enable programmable receptor-mediated gene delivery. First, we genetically encode small targeting scaffolds into a variable region of an AAV capsid and show that this redirects tropism toward the receptor recognized by these targeting scaffolds and also renders this AAV variant resistant to neutralizing antibodies present in nonhuman primate serum. We then simplify retargeting of tropism by engineering the same variable loop to encode a HUH tag, which forms a covalent bond to single-stranded DNA oligos conjugated to store-bought antibodies. We demonstrate that retargeting this HUH-AAVs toward different receptors is as simple as "arming" a premade noninfective AAV template with a different antibody in a conjugation process that uses widely available reagents and requires no optimization or extensive purification. Composite antibody-AAV nanoparticles structurally separate tropism and payload encapsulation, allowing each to be engineered independently.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31809024      PMCID: PMC7676631          DOI: 10.1021/acs.bioconjchem.9b00790

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  70 in total

1.  Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates.

Authors:  T Sano; C L Smith; C R Cantor
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

2.  A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins.

Authors:  Ulrich Rothbauer; Kourosh Zolghadr; Serge Muyldermans; Aloys Schepers; M Cristina Cardoso; Heinrich Leonhardt
Journal:  Mol Cell Proteomics       Date:  2007-10-21       Impact factor: 5.911

3.  Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.

Authors:  Joshua C Grieger; Stephen M Soltys; Richard Jude Samulski
Journal:  Mol Ther       Date:  2015-10-06       Impact factor: 11.454

4.  Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer.

Authors:  Alexander Muik; Johanna Reul; Thorsten Friedel; Anke Muth; Karen Patricia Hartmann; Irene C Schneider; Robert C Münch; Christian J Buchholz
Journal:  Biomaterials       Date:  2017-07-25       Impact factor: 12.479

5.  Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors.

Authors:  Martin U Ried; Anne Girod; Kristin Leike; Hildegard Büning; Michael Hallek
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 6.  Basic biology of adeno-associated virus (AAV) vectors used in gene therapy.

Authors:  Balaji Balakrishnan; Giridhara R Jayandharan
Journal:  Curr Gene Ther       Date:  2014       Impact factor: 4.391

7.  Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.

Authors:  Robert C Münch; Hanna Janicki; Iris Völker; Anke Rasbach; Michael Hallek; Hildegard Büning; Christian J Buchholz
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

8.  Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.

Authors:  Oliver J Müller; Felix Kaul; Matthew D Weitzman; Renata Pasqualini; Wadih Arap; Jürgen A Kleinschmidt; Martin Trepel
Journal:  Nat Biotechnol       Date:  2003-08-03       Impact factor: 54.908

9.  In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.

Authors:  Dirk Grimm; Joyce S Lee; Lora Wang; Tushar Desai; Bassel Akache; Theresa A Storm; Mark A Kay
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

Review 10.  Properties, production, and applications of camelid single-domain antibody fragments.

Authors:  M M Harmsen; H J De Haard
Journal:  Appl Microbiol Biotechnol       Date:  2007-08-18       Impact factor: 4.813

View more
  4 in total

1.  Molecular underpinnings of ssDNA specificity by Rep HUH-endonucleases and implications for HUH-tag multiplexing and engineering.

Authors:  Kassidy J Tompkins; Mo Houtti; Lauren A Litzau; Eric J Aird; Blake A Everett; Andrew T Nelson; Leland Pornschloegl; Lidia K Limón-Swanson; Robert L Evans; Karen Evans; Ke Shi; Hideki Aihara; Wendy R Gordon
Journal:  Nucleic Acids Res       Date:  2021-01-25       Impact factor: 16.971

Review 2.  Synthetic Biology: Emerging Concepts to Design and Advance Adeno-Associated Viral Vectors for Gene Therapy.

Authors:  Hanna J Wagner; Wilfried Weber; Martin Fussenegger
Journal:  Adv Sci (Weinh)       Date:  2021-02-26       Impact factor: 16.806

Review 3.  Fantastic AAV Gene Therapy Vectors and How to Find Them-Random Diversification, Rational Design and Machine Learning.

Authors:  Jonas Becker; Julia Fakhiri; Dirk Grimm
Journal:  Pathogens       Date:  2022-07-03

Review 4.  Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification.

Authors:  Maxim A Korneyenkov; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.